Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Phase III NCT06872892

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis — Recruiting • Phase III • Respiratory / COPD / Asthma • NCT06872892.

📅 02 Apr 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase III
NCT ID
NCT06872892
Sponsor
Boehringer Ingelheim
Start
2025-06-09
ClinicaliQ Trial Snapshot
  • The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis — Recruiting • Phase III • Respiratory / COPD / Asthma • NCT06872892.
  • This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether….
  • Sponsor: Boehringer Ingelheim.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medicine.…

Eligibility Snapshot
  • : * Male or female participants. Woman of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per International Council of Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1 % per year when used consistently and correctly, as well as one barrier method. A list of contraception methods meeting these criteria is provided in the participant information. * Signed and dated written informed consent and assent, if applicable, prior to admission to the study, in accordance with GCP and local legislation. * Age of participants when signing the informed consent/assent ≥12 years. -- Adolescents need to weigh at least 35 kg at Visit 1. * Clinical history consistent with bronchiectasis (e.g. cough, chronic sputum production, recurrent respiratory infections) and investigator confirmed diagnosis of bronchiectasis by CT scan where bronchiectasis has been documented by a radiologist. Participants whose past CT scan image records are not available will undergo a chest CT scan during Screening. Historical scans must not be older than five years. * Adult participants should be able to produce sputum for Pseudomonas aeruginosa assessment during the screening period. * History of documented pulmonary exacerbations…

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
IVF staff accused of misleading UK parents about sperm and egg donors in northern Cyprus
Respiratory / COPD / Asthma · BBC Health · 18 Aug 2026
Parents undergoing IVF in northern Cyprus may have had their selected donors substituted without consent, raising serious ethical and legal concerns that…
View brief →
Clinical Brief
Over one million children referred for mental healthcare – with anxiety the main reason
Respiratory / COPD / Asthma · BBC Health · 29 Jun 2026
Over one million children in England have been referred for mental healthcare, with anxiety as the leading presenting complaint, indicating a substantial…
View brief →
Guideline
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over (terminated evaluation)
Respiratory / COPD / Asthma · 25 Aug 2026
Evaluation terminated: Brensocatib for non-CF bronchiectasis is no longer under NICE appraisal—do not initiate new treatment pathways for this indication pending alternative…
View guideline →
Clinical Brief
Your tips on getting a fussy child to eat, and six recipes they’ll love
Respiratory / COPD / Asthma · BBC Health · 21 Jul 2026
Model healthy eating behaviours and involve children in meal planning and food preparation to increase acceptance of nutritious foods like vegetables Offer…
View brief →
Clinical Brief
RSV vaccination: expansion of eligibility to older adults in certain clinical risk groups
Respiratory / COPD / Asthma · NHS England · 01 Jul 2026
From September 2026, RSV vaccination eligibility expands beyond the current age-based criteria to include older adults in specific clinical risk groups, requiring…
View brief →
Clinical Brief
How can we keep children safe during the heatwave?
Respiratory / COPD / Asthma · BBC Health · 24 Jun 2026
Monitor children for heat-related illness signs including excessive drowsiness, confusion, and lack of sweating, as they are more vulnerable to rapid temperature…
View brief →